ERBB2 and breast carcinoma: Given the lack of successful targeted therapies currently available for the treatment of TNBC, and the superior clinical relevance of using PDX cultures as opposed to cell lines for assessing drug response in cancer37, we first sought to identify effective targeted agents through drug screening of breast cancer PDXs: basal-like TNBC (HCI01, HCI16, UCD52, WHIM2, WHIM30), luminal androgen receptor (LAR) subtype TNBC (HCI09), luminal ER-positive (HCI03, HCI11, HCI13), and HER2-enriched (HCI08).